| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0733-8651(03)00115-2 |
| P698 | PubMed publication ID | 14994847 |
| P50 | author | Daniel E. Singer | Q110881174 |
| Margaret C. Fang | Q124660446 | ||
| P2860 | cites work | Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial | Q28142719 |
| Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation | Q28165271 | ||
| Antithrombotic therapy in atrial fibrillation | Q28175172 | ||
| Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS) | Q28190393 | ||
| Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study | Q28191755 | ||
| Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 | ||
| Warfarin, aspirin, or both after myocardial infarction | Q28193836 | ||
| Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis | Q28194233 | ||
| The underutilization of cardiac medications of proven benefit, 1990 to 2002 | Q28194871 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
| Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins | Q29620720 | ||
| Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study | Q31522746 | ||
| Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin | Q33671179 | ||
| Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis | Q33744558 | ||
| Why do patients with atrial fibrillation not receive warfarin? | Q33815598 | ||
| Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs | Q33815844 | ||
| Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
| ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co | Q34093427 | ||
| Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience | Q34127331 | ||
| A comparison of rate control and rhythm control in patients with atrial fibrillation | Q34162727 | ||
| Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study | Q34186228 | ||
| Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography | Q74429767 | ||
| Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation | Q77178177 | ||
| Risk of thromboembolic events in patients with atrial flutter | Q77225703 | ||
| Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis | Q77750586 | ||
| A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial | Q78175773 | ||
| A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation | Q78613787 | ||
| Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation | Q34372459 | ||
| Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators | Q34506737 | ||
| Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective | Q35824979 | ||
| Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion | Q36931437 | ||
| Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation | Q40382719 | ||
| Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram | Q40903175 | ||
| Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation | Q41023264 | ||
| Epidemiology and mechanism of atrial fibrillation and atrial flutter | Q41197972 | ||
| Risk factors for intracranial hemorrhage in outpatients taking warfarin | Q42285556 | ||
| Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group | Q42287205 | ||
| Thromboembolism in chronic atrial flutter: is the risk underestimated? | Q43478232 | ||
| Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages | Q43505750 | ||
| Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation | Q43603177 | ||
| Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study | Q43655233 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study | Q43750037 | ||
| Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators | Q43764537 | ||
| Canadian atrial fibrillation anticoaguiation (CAFA) study | Q43928649 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial | Q44054411 | ||
| Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke | Q44075681 | ||
| The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation | Q44153210 | ||
| National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation | Q44725124 | ||
| Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia | Q45038588 | ||
| Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups | Q48090061 | ||
| Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke | Q48398555 | ||
| Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry | Q48940188 | ||
| An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation | Q48940645 | ||
| Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis | Q49173787 | ||
| Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. | Q50633316 | ||
| Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperat | Q50658605 | ||
| Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. | Q50663539 | ||
| Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. | Q52229885 | ||
| Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. | Q53333711 | ||
| Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. | Q53352979 | ||
| Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. | Q53360138 | ||
| Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. | Q53763856 | ||
| Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. | Q54114563 | ||
| Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial | Q56659254 | ||
| Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation | Q59542153 | ||
| Impact of the maze procedure on the stroke rate in patients with atrial fibrillation | Q61648622 | ||
| Stroke Prevention in Atrial Fibrillation Study. Final results | Q67925848 | ||
| The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation | Q70105143 | ||
| The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study | Q70700194 | ||
| Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy | Q71264573 | ||
| The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life | Q71493673 | ||
| Warfarin for atrial fibrillation. The patient's perspective | Q71493675 | ||
| Patient preferences for stroke outcomes | Q72157125 | ||
| A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group | Q73951222 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atrial fibrillation | Q815819 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 47-62 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Cardiology clinics | Q2600141 |
| P1476 | title | Anticoagulation for atrial fibrillation | |
| P478 | volume | 22 |
Search more.